Alendronate treatment of naturally-occurring periodontitis in beagle dogs.
The treatment of periodontal disease has been largely directed at the microbiological etiology. The prevention of bone loss by modulating the host response to the bacteria may be a useful adjunctive method in the management of periodontitis. Alendronate, an amino bisphosphonate, may inhibit bone loss in osteolytic diseases by altering osteoclast activity. The objective of this double-blind study was to evaluate alendronate inhibition of alveolar bone loss in the naturally occurring beagle dog model of periodontitis. Sixteen 7 to 9 year old beagles with moderate-to-severe periodontitis were studied for 6 months. The dogs were stratified into two groups based on initial periodontal severity. One group received 3.0 mg/kg alendronate weekly orally and the other group received a placebo. Silk ligatures were placed on the study teeth for the first 3 months of the study to exacerbate the periodontal destruction. Clinical data were collected for attachment level, gingival index, plaque index, and mobility at baseline and one-month intervals. Intraoral radiographs were made at baseline and at 3 and 6 months. The mandibles were processed for histology at month 6. The radiographs were analyzed by digital image analysis of the subtracted images. A statistically significant difference in bone mass (P < 0.001) was observed between the alendronate and placebo groups. The bisphosphonate had no effect on the clinical parameters of gingival inflammation or plaque. A trend toward decreased attachment loss and mobility was observed in favor of the alendronate group.(ABSTRACT TRUNCATED AT 250 WORDS)
Reddy
M S
MS
University of Alabama, School of Dentistry, Department of Periodontics, Birmingham, USA.
Weatherford
T W
TW
Smith
C A
CA
West
B D
BD
Jeffcoat
M K
MK
Jacks
T M
TM
D019386:Alendronate; D016301:Alveolar Bone Loss / Q000517:prevention & control*; D000704:Analysis of Variance; D000818:Animals; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004285:Dogs; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005260:Female; D010518:Periodontitis / Q000188:drug therapy*
D004164:Diphosphonates; D019386:Alendronate